Moleculin Biotech, Inc. (MBRX) News

Moleculin Biotech, Inc. (MBRX): $1.70

-0.01 (-0.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MBRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 454

in industry

Filter MBRX News Items

MBRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MBRX News Highlights

  • For MBRX, its 30 day story count is now at 5.
  • Over the past 13 days, the trend for MBRX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • MG and DRUG are the most mentioned tickers in articles about MBRX.

Latest MBRX News From Around the Web

Below are the latest news stories about Moleculin Biotech Inc that investors may wish to consider to help them evaluate MBRX as an investment opportunity.

Moleculin Biotech Annamycin Doublet Therapy Shows 68% Overall Survival In Animal Study

Moleculin Biotech Inc (NASDAQ: MBRX ) has announced preliminary results supporting the successful conclusion of its second Phase 1 trial in Poland, evaluating Annamycin for relapsed and refractory acute myeloid leukemia (AML). Moleculin determined a dose of 240 mg/m2 as the Recommended Phase 2 Dose (RP2D), subject to final approval of the Safety Review Full story available on Benzinga.com

Benzinga | February 14, 2022

Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced preliminary results supporting the successful conclusion of its second Phase 1 trial (MB-105) in Poland evaluating Annamycin for the treatment of relapsed and refractory acute myeloid leukemia (AML), where Moleculin determined a dose of 240 mg/m2 as the Recommended Phase 2 Dose (RP2

Yahoo | February 14, 2022

Moleculin Biotech (MBRX) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Moleculin Biotech (MBRX – Research Report) on February 2 and set a price target of $5.00. The company's shares closed last Friday at $1.49, close to its 52-week low of $1.31. According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moleculin Biotech.

Catie Powers on TipRanks | February 6, 2022

Companies Like Moleculin Biotech (NASDAQ:MBRX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | February 1, 2022

Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks Conference

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter V. Klemp, Founder, President, CEO and Chairman, will participate in the Virtual Investor 2022 Top Picks Conference on Thursday, January 27, 2022 at 9:00 AM ET.

Yahoo | January 20, 2022

Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported that it has received an updated independent safety review of certain preliminary data for the first 30 patients in its three Phase 1 clinical trials with Annamycin targeting relapsed or refractory acute myeloid leukemia (AML) and the metastases of soft tissue sarcoma to the lungs (ST

Yahoo | January 18, 2022

JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th

\- Access the event and schedule of presenting companies at virtualinvestorco.com -\- Live video webcast presentations of participating companies followed by interactive Q&A session -PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 /JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2022 Top Picks Conference January 25-27, 2022.

Yahoo | January 12, 2022

Moleculin to Present at the H.C. Wainwright BioConnect Conference

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022.

Yahoo | January 7, 2022

Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported preliminary interim results from its U.S. Phase 1b/2 clinical trial as it concluded the safety review of the third cohort and opens the fourth cohort in a dose escalation trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases, which continues to doc

Yahoo | December 27, 2021

State Street Corp Purchases New Holdings in Moleculin Biotech, Inc. (NASDAQ:MBRX)

State Street Corp purchased a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 59,900 shares of the companys stock, valued at approximately $220,000. State Street Corp owned about 0.21% of Moleculin []

Dakota Financial News | December 10, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4659 seconds.